TrialBMJ open2024

Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19).

Ranjani Somayaji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.